COVID-19 Drug Shows Promise in Early Trials
An experimental drug has shown promising results in treating severe COVID-19 symptoms. The drug, developed by an unidentified entity, has successfully completed the first watch phase of trials at Tel Aviv's Ichilov Hospital. It is expected to be widely available within months.
The drug, administered as a daily spray, improved breathing and increased blood oxygen levels in all 30 patients during the first watch. It targets the protein CD24 to regulate the immune system's response to the virus. No side effects were reported, thanks to its nanotechnology-based delivery system and use of a naturally occurring substance.
The full research cycle is expected to be completed by the end of the year. The next phase, involving several hundred patients, will follow. The second phase, starting soon, will involve 100 patients, with half receiving the drug and half a placebo. Upon completion and necessary permits, the drug is set to be released as an ordinary spray for home use.
The experimental drug's success in the first watch phase of trials brings hope for a new treatment option against severe COVID-19 symptoms. With no reported side effects and a quick, cost-effective production process, it could soon be distributed worldwide. Further trials will determine its wider applicability and safety.
